Limitations to the use of carboplatin-based therapy in advanced ovarian cancer
about
HM015k, a Novel Silybin Derivative, Multi-Targets Metastatic Ovarian Cancer Cells and Is Safe in Zebrafish Toxicity StudiesComparison of Hypersensitivity Reactions to Carboplatin Retreatment in Gynecologic Cancer Patients between One and Two Hour Infusions: a Randomized Trial StudyPlatinum or nonplatinum in recurrent ovarian cancer: that is the question.
P2860
Limitations to the use of carboplatin-based therapy in advanced ovarian cancer
description
2014 nî lūn-bûn
@nan
2014年の論文
@ja
2014年学术文章
@wuu
2014年学术文章
@zh-cn
2014年学术文章
@zh-hans
2014年学术文章
@zh-my
2014年学术文章
@zh-sg
2014年學術文章
@yue
2014年學術文章
@zh
2014年學術文章
@zh-hant
name
Limitations to the use of carboplatin-based therapy in advanced ovarian cancer
@ast
Limitations to the use of carboplatin-based therapy in advanced ovarian cancer
@en
type
label
Limitations to the use of carboplatin-based therapy in advanced ovarian cancer
@ast
Limitations to the use of carboplatin-based therapy in advanced ovarian cancer
@en
prefLabel
Limitations to the use of carboplatin-based therapy in advanced ovarian cancer
@ast
Limitations to the use of carboplatin-based therapy in advanced ovarian cancer
@en
P2860
P1433
P1476
Limitations to the use of carboplatin-based therapy in advanced ovarian cancer
@en
P2860
P356
10.1016/S1359-6349(15)70005-4
P577
2014-12-01T00:00:00Z